In addition, the use of TNF inhibitors should be restricted in VEXAS patients due to the heightened risk of onco-hematological disorders, reported for both VEXAS syndrome and the use of anti-TNF agents (Gurnari et al., 2024b; Berghen et al., 2015; Wu et al., 2014). The gene discussed is TNF; the disease is VEXAS syndrome.